179 related articles for article (PubMed ID: 18347908)
1. Perceived stress is associated with impaired T-cell response to HPV16 in women with cervical dysplasia.
Fang CY; Miller SM; Bovbjerg DH; Bergman C; Edelson MI; Rosenblum NG; Bove BA; Godwin AK; Campbell DE; Douglas SD
Ann Behav Med; 2008 Feb; 35(1):87-96. PubMed ID: 18347908
[TBL] [Abstract][Full Text] [Related]
2. HPV-16 E7-Specific Cellular Immune Response in Women With Cervical Intraepithelial Lesion Contributes to Viral Clearance: A Cross-Sectional and Longitudinal Clinical Study.
Zhang L; Shi X; Zhang Q; Mao Z; Shi X; Zhou J; Jian A; Zhu R; Jiang S; Lu W
Front Immunol; 2021; 12():768144. PubMed ID: 35095843
[TBL] [Abstract][Full Text] [Related]
3. Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C.
Da Silva DM; Woodham AW; Skeate JG; Rijkee LK; Taylor JR; Brand HE; Muderspach LI; Roman LD; Yessaian AA; Pham HQ; Matsuo K; Lin YG; McKee GM; Salazar AM; Kast WM
Clin Immunol; 2015 Dec; 161(2):197-208. PubMed ID: 26360252
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia.
de Gruijl TD; Bontkes HJ; Walboomers JM; Schiller JT; Stukart MJ; Groot BS; Chabaud MM; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
J Natl Cancer Inst; 1997 May; 89(9):630-8. PubMed ID: 9150187
[TBL] [Abstract][Full Text] [Related]
5. Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years.
Paaso A; Koskimaa HM; Welters MJ; Grénman S; Syrjänen K; van der Burg SH; Syrjänen S
J Transl Med; 2015 May; 13():163. PubMed ID: 25990808
[TBL] [Abstract][Full Text] [Related]
6. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
7. T cell receptor repertoire among women who cleared and failed to clear cervical human papillomavirus infection: An exploratory proof-of-principle study.
Lang Kuhs KA; Lin SW; Hua X; Schiffman M; Burk RD; Rodriguez AC; Herrero R; Abnet CC; Freedman ND; Pinto LA; Hamm D; Robins H; Hildesheim A; Shi J; Safaeian M
PLoS One; 2018; 13(1):e0178167. PubMed ID: 29385144
[TBL] [Abstract][Full Text] [Related]
8. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia.
Kadish AS; Ho GY; Burk RD; Wang Y; Romney SL; Ledwidge R; Angeletti RH
J Natl Cancer Inst; 1997 Sep; 89(17):1285-93. PubMed ID: 9293919
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort.
Koskimaa HM; Paaso AE; Welters MJ; Grénman SE; Syrjänen KJ; van der Burg SH; Syrjänen SM
J Transl Med; 2014 Feb; 12():44. PubMed ID: 24524328
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
11. Human papilloma virus infection of uterine cervix and spectrum of cervical pathology in human immunodeficiency virus/AIDS.
Jain BB; Adhikary T; Sadhukhan PC; Nandi A
J Cancer Res Ther; 2021; 17(6):1462-1467. PubMed ID: 34916378
[TBL] [Abstract][Full Text] [Related]
12. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).
Kaufmann AM; Nieland JD; Jochmus I; Baur S; Friese K; Gabelsberger J; Gieseking F; Gissmann L; Glasschröder B; Grubert T; Hillemanns P; Höpfl R; Ikenberg H; Schwarz J; Karrasch M; Knoll A; Küppers V; Lechmann M; Lelle RJ; Meissner H; Müller RT; Pawlita M; Petry KU; Pilch H; Walek E; Schneider A
Int J Cancer; 2007 Dec; 121(12):2794-800. PubMed ID: 17721997
[TBL] [Abstract][Full Text] [Related]
13. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection.
Haupt RM; Wheeler CM; Brown DR; Garland SM; Ferris DG; Paavonen JA; Lehtinen MO; Steben M; Joura EA; Giacoletti KE; Radley DR; James MK; Saah AJ; Sings HL;
Int J Cancer; 2011 Dec; 129(11):2632-42. PubMed ID: 21491420
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6.
de Jong A; van Poelgeest MI; van der Hulst JM; Drijfhout JW; Fleuren GJ; Melief CJ; Kenter G; Offringa R; van der Burg SH
Cancer Res; 2004 Aug; 64(15):5449-55. PubMed ID: 15289354
[TBL] [Abstract][Full Text] [Related]
15. Multiple human papillomavirus infection with or without type 16 and risk of cervical intraepithelial neoplasia among women with cervical cytological abnormalities.
Spinillo A; Gardella B; Roccio M; Alberizzi P; Cesari S; Patrizia M; Silini E
Cancer Causes Control; 2014 Dec; 25(12):1669-76. PubMed ID: 25296710
[TBL] [Abstract][Full Text] [Related]
16. [Prevalence of high-risk HPV and its distribution in cervical precancerous lesions among 35-64 years old women who received cervical cancer screening in Beijing].
Shen J; Gao LL; Zhang Y; Han LL; Wang JD
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 May; 52(5):493-497. PubMed ID: 29747341
[No Abstract] [Full Text] [Related]
17. Co-infections of HPV16/18 with other high-risk HPV types and the risk of cervical carcinogenesis: A large population-based study.
Wu P; Xiong H; Yang M; Li L; Wu P; Lazare C; Cao C; Gao P; Meng Y; Zhi W; Lin S; Hu J; Wei J; Ma D; Liu J; Yin P; Xing H
Gynecol Oncol; 2019 Dec; 155(3):436-443. PubMed ID: 31604662
[TBL] [Abstract][Full Text] [Related]
18. Identification of promiscuous HPV16-derived T helper cell epitopes for therapeutic HPV vaccine design.
Grabowska AK; Kaufmann AM; Riemer AB
Int J Cancer; 2015 Jan; 136(1):212-24. PubMed ID: 24824905
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia.
Yang W; Song Y; Lu YL; Sun JZ; Wang HW
Immunology; 2013 Aug; 139(4):513-22. PubMed ID: 23521696
[TBL] [Abstract][Full Text] [Related]
20. Association of cervical precancer with human papillomavirus types other than 16 among HIV co-infected women.
Massad LS; Xie X; Burk RD; D'Souza G; Darragh TM; Minkoff H; Colie C; Burian P; Palefsky J; Atrio J; Strickler HD
Am J Obstet Gynecol; 2016 Mar; 214(3):354.e1-6. PubMed ID: 26433170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
